Medera
PrivateLast Round
M&A
Feb 26, 2026
Est. Valuation
$100M
Total Funding Raised
$3.03M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Medera is a clinical-stage biopharmaceutical company that develops novel gene- and cell-based therapeutic candidates for cardiovascular, pulmonary, and vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Medera Comparables
Compare Medera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| bit.bio | 84% | |
| Axol Bioscience | 84% | |
| Ncardia | 84% |
Medera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Feb 26, 2026 | ||||
| Reverse Merger | Sep 5, 2024 | ||||
| M&A | Nov 18, 2020 | ||||
| Grant | Jan 7, 2020 | ||||
| Grant | Jun 6, 2018 | ||||
Grant | Feb 26, 2018 |
Key People
Founding team and executive leadership
Medera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hong Kong Science and Technology Parks Corporation | Private Placement, VC Round |
| Innovation and Technology Commission | Grant |
| Keen Vision Acquisition Corporation | Reverse Merger, M&A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 135% MoM, reaching 4.2K.
- Nov 8, 2025
Monthly visitors increased 126% MoM, from 3.9K to 8.9K.
Recent news
Latest coverage and updates
- attends_eventAug 31, 2026
Medera Inc. attended event European Society of Cardiology (ESC) Congress 2026 on Aug 28th '26.
- attends_eventAug 31, 2026
Medera Inc. attended event ESC Congress 2026 on Aug 28th '26.
- is_developingAug 24, 2026
Medera Inc. is developing adeno-associated virus-based gene therapies for difficult-to-treat cardiovascular conditions on Aug 24th '26.
Medera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Medera's valuation, stock price, and market status.
Is Medera a public or private company?
Medera is a private company.
What is the current stock price of Medera?
Medera is a private company with no public stock price. Caplight tracks Medera's secondary market activity and provides MarketPrice estimates to Caplight users.
How much is Medera worth (valuation)?
Medera's valuation is estimated at $100.0M based on funding round data.
Can I buy Medera stock?
Medera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Medera's last funding round?
Medera's most recent funding round was M&A on February 26, 2026.
Who are the main investors in Medera?
Key investors in Medera include Hong Kong Science and Technology Park, Innovation and Technology Commission, Keen Vision Acquisition Corporation.
Will Medera IPO soon?
No public IPO plans have been announced for Medera.
How can I track Medera secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Medera's secondary market activity and sign up for updates.